Document:

<PAGE>

                                                                   Exhibit 10.20

                          LIGHT SCIENCES ONCOLOGY, INC.

                  SECOND AMENDED AND RESTATED VOTING AGREEMENT

     THIS SECOND AMENDED AND RESTATED VOTING AGREEMENT (this "AGREEMENT") is
made as of December 12, 2005 (the "EFFECTIVE DATE"), by and among Light Sciences
Oncology, Inc., a Washington corporation (the "COMPANY"), the holders of the
Company's Common Stock listed on Schedule I hereto (the "COMMON HOLDERS"), and
the holders of the Company's Series A Preferred Stock listed on Schedule II
hereto (the "INVESTORS").

                                    RECITALS

     WHEREAS, the Common Holders and certain Investors (collectively, the "PRIOR
HOLDERS") are parties to that certain Amended and Restated Voting Agreement
dated December 8, 2005 (the "PRIOR AGREEMENT");

     WHEREAS, the Company and Novo A/S ("NOVO"), among others, are entering into
that certain Series A Preferred Stock Purchase Agreement, dated as of October 6,
2005, as amended (the "SERIES A AGREEMENT"), pursuant to which Novo will
purchase shares of the Series A Preferred Stock of the Company (the "SERIES A
PREFERRED"), and it is a condition to the closing of the sale of the Series A
Preferred to Novo that Novo and the Company execute and deliver this Agreement;

     WHEREAS, it is a further condition to the closing of the sale of the Series
A Preferred to Novo pursuant to the Purchase Agreement that Prior Holders
holding sufficient shares to amend the Prior Agreement execute and deliver this
Agreement and agree that this Agreement will supersede and replace the Prior
Agreement in its entirety; and

     WHEREAS, the Company and the Prior Holders desire to amend and restate the
Prior Agreement and to enter into this Agreement with Novo.

     NOW, THEREFORE, in consideration of the mutual promises and covenants
hereinafter set forth, the Company and the Prior Holders hereby agree that the
Prior Agreement is terminated and superseded in its entirety by this Agreement,
and all parties agree as follows:

                                    AGREEMENT

     1.   BOARD OF DIRECTORS.

     (a) During the term of this Agreement, the Board of Directors of the
Company shall have seven (7) authorized members.

     (b) During the term of this Agreement, each of the Common Holders and the
Investors agrees to vote (whether by unanimous written consent or at a meeting
of shareholders) all shares of capital stock of the Company now or hereafter
owned by them to elect to the Company's board of directors:

<PAGE>

          (i) one (1) nominee (the "ESSEX NOMINEE") designated by Essex
Woodlands Health Ventures Fund VI, L.P. ("ESSEX") provided that if either (A)
Essex and its affiliates no longer hold at least 25% of the shares originally
purchased by Essex under the Series A Agreement, or (B) if Essex declines in
writing to designate an Essex Nominee (x) in the case of action by written
consent, at the time such consent is distributed to all shareholders, or (y) in
the case of action at a meeting of shareholders, at least 10 days prior to the
meeting, then the holders of a majority of the shares of Series A Preferred held
by the Investors shall be entitled to select the Essex Nominee;

          (ii) one (1) nominee (the "INVESTOR NOMINEE") designated by the
holders of a majority of the shares of Series A Preferred held by the Investors,
so long as at least 600,000 shares of Series A Preferred (as adjusted for any
stock dividends, combinations, splits, recapitalizations and the like) are
outstanding;

          (iii) one (1) nominee (the "COMMON NOMINEE") designated by the holders
of a majority of the shares of Common Stock held by the Common Holders;

          (iv) one (1) person (the "CEO NOMINEE") who shall be the Chief
Executive Officer of the Company;

          (v) one (1) nominee (the "INDEPENDENT NOMINEE") designated by a
majority of the directors on the Company's Board of Directors, which Independent
Nominee would qualify as an independent director (as defined in Rule 4200(a)(15)
of the National Association of Securities' Dealers Listing Standards, as may be
modified or supplemented);

          (vi) one (1) nominee (the "SLS NOMINEE") designated by SLS provided
that if either (A) SLS and its affiliates no longer hold at least 25% of the
shares originally purchased by SLS under the Series A Agreement, or (B) if SLS
declines in writing to designate a SLS Nominee (x) in the case of action by
written consent, at the time such consent is distributed to all shareholders, or
(y) in the case of action at a meeting of shareholders, at least 10 days prior
to the meeting, then the holders of a majority of the shares of Series A
Preferred held by the Investors shall be entitled to select the SLS Nominee; and

          (vii) one (1) nominee (the "NOVO NOMINEE") designated by Novo provided
that if either (A) Novo and its affiliates no longer hold at least 25% of the
shares originally purchased by Novo under the Series A Agreement, or (B) if Novo
declines in writing to designate a Novo Nominee (x) in the case of action by
written consent, at the time such consent is distributed to all shareholders, or
(y) in the case of action at a meeting of shareholders, at least 10 days prior
to the meeting, then the holders of a majority of the shares of Series A
Preferred held by the Investors shall be entitled to select the Novo Nominee.

     (c) By their execution of this Agreement, the parties hereto consent to the
appointment of Jeff Himawan as the initial Essex Nominee, Craig Taylor as the
initial Investor Nominee, Craig Watjen as the initial Common Nominee, Llew
Keltner as the initial CEO Nominee, Richard Whitney as the initial Independent
Nominee, Martin Olin Andersen as the initial SLS Nominee, and Ulrik Spork as the
initial Novo Nominee, each to serve until the next

                                       -2-

<PAGE>

annual meeting of the Company or until their earlier resignation or removal in
accordance with the terms of this Agreement and the by-laws of the Company.

     (d) If Essex gives notice at any time to the Company (which notice shall be
promptly communicated by the Company to the Common Holders and the other
Investors) that the individual then serving as a director of the Company as the
Essex Nominee is no longer its designee, then the parties hereto shall take all
such actions as are necessary to remove such individual from the Board of
Directors. If the holders of a majority of the shares of Series A Preferred then
held by the Investors give Essex notice at any time that they would like to
remove the individual then serving as a director of the Company as the Essex
Nominee, and in response Essex either consents in writing to such decision or
agrees in writing that it does not then wish to control the designation of the
Essex Director, then such majority holders may then give notice to the Company
(which notice shall be promptly communicated by the Company to the Common
Holders and the other Investors) that the individual then serving as a director
of the Company as the Essex Nominee is no longer their designee, and then the
parties hereto shall take all such actions as are necessary to remove such
individual from the Board of Directors. If the Essex Nominee dies, resigns or is
removed as a director of the Company pursuant to this Section 1(d), then the
parties hereto shall take such action as is necessary to elect as a director of
the Company any individual subsequently designated pursuant to the terms of
Section 1(b)(i) above.

     (e) If the holders of a majority of the shares of Series A Preferred then
held by the Investors give notice at any time to the Company (which notice shall
be promptly communicated by the Company to the Common Holders and the other
Investors) that the individual then serving as a director of the Company as the
Investor Nominee is no longer their designee, then the parties hereto shall take
all such actions as are necessary to remove such individual from the Board of
Directors. If the Investor Nominee dies, resigns or is removed as a director of
the Company pursuant to this Section 1(e), then the parties hereto shall take
such action as is necessary to elect as a director of the Company any individual
subsequently designated pursuant to the terms of Section 1(b)(ii) above.

     (f) If the holders of a majority of the shares of Common Stock then held by
the Common Holders give notice at any time to the Company (which notice shall be
promptly communicated by the Company to the other Common Holders and the
Investors) that the individual then serving as a director of the Company as the
Common Nominee is no longer their designee, then the parties hereto shall take
all such actions as are necessary to remove such individual from the Board of
Directors. If the Common Nominee dies, resigns or is removed as a director of
the Company pursuant to this Section 1(f), then the parties hereto shall take
such action as is necessary to elect as a director of the Company any individual
subsequently designated pursuant to the terms of Section 1(b)(iii) above.

     (g) If the individual serving as the CEO Nominee ceases for any reason to
be the Chief Executive Officer of the Company (notice of which event shall be
promptly communicated by the Company to the Common Holders and the Investors),
then the parties hereto shall take all such actions as are necessary to remove
such individual from the Board of Directors. If the CEO Nominee dies, resigns or
is removed as a director of the Company pursuant to this Section 1(g), then the
parties hereto shall take such action as is necessary to elect as a director of
the Company any individual subsequently qualified pursuant to the terms of
Section 1(b)(iv) above.

                                       -3-

<PAGE>

     (h) If a majority of the directors on the Board of Directors (other than
the Independent Nominee) give notice at any time to the Company (which notice
shall be promptly communicated by the Company to the Common Holders and the
Investors) that the individual then serving as a director of the Company as the
Independent Nominee is no longer their designee, then the parties hereto shall
take all such actions as are necessary to remove such individual from the Board
of Directors. If the Independent Nominee dies, resigns or is removed as a
director of the Company pursuant to this Section 1(h), then the parties hereto
shall take such action as is necessary to elect as a director of the Company any
individual subsequently designated pursuant to the terms of Section 1(b)(v)
above.

     (i) If SLS gives notice at any time to the Company (which notice shall be
promptly communicated by the Company to the Common Holders and the other
Investors) that the individual then serving as a director of the Company as the
SLS Nominee is no longer its designee, then the parties hereto shall take all
such actions as are necessary to remove such individual from the Board of
Directors. If the holders of a majority of the shares of Series A Preferred then
held by the Investors give SLS notice at any time that they would like to remove
the individual then serving as a director of the Company as the SLS Nominee, and
in response SLS either consents in writing to such decision or agrees in writing
that it does not then wish to control the designation of the SLS Director, then
such majority holders may then give notice to the Company (which notice shall be
promptly communicated by the Company to the Common Holders and the other
Investors) that the individual then serving as a director of the Company as the
SLS Nominee is no longer their designee, and then the parties hereto shall take
all such actions as are necessary to remove such individual from the Board of
Directors. If the SLS Nominee dies, resigns or is removed as a director of the
Company pursuant to this Section 1(i), then the parties hereto shall take such
action as is necessary to elect as a director of the Company any individual
subsequently designated pursuant to the terms of Section 1(b)(vi) above.

     (j) If Novo gives notice at any time to the Company (which notice shall be
promptly communicated by the Company to the Common Holders and the other
Investors) that the individual then serving as a director of the Company as the
Novo Nominee is no longer its designee, then the parties hereto shall take all
such actions as are necessary to remove such individual from the Board of
Directors. If the holders of a majority of the shares of Series A Preferred then
held by the Investors give Novo notice at any time that they would like to
remove the individual then serving as a director of the Company as the Novo
Nominee, and in response Novo either consents in writing to such decision or
agrees in writing that it does not then wish to control the designation of the
Novo Director, then such majority holders may then give notice to the Company
(which notice shall be promptly communicated by the Company to the Common
Holders and the other Investors) that the individual then serving as a director
of the Company as the Novo Nominee is no longer their designee, and then the
parties hereto shall take all such actions as are necessary to remove such
individual from the Board of Directors. If the Novo Nominee dies, resigns or is
removed as a director of the Company pursuant to this Section 1(j), then the
parties hereto shall take such action as is necessary to elect as a director of
the Company any individual subsequently designated pursuant to the terms of
Section 1(b)(vii) above.

     (k) If requested by an Essex Nominee (or Essex), Investor Nominee, Common
Nominee, CEO Nominee, Independent Nominee, SLS Nominee (or SLS) or Novo Nominee
(or Novo) at any time, the Company shall enter into an Indemnification Agreement
in the form

                                       -4-

<PAGE>

attached hereto as Exhibit A with the Essex Nominee, Investor Nominee, Common
Nominee, CEO Nominee, Independent Nominee, SLS Nominee or the Novo Nominee as
applicable, then serving as director or being elected to do so.

     (k) The Company shall use its commercially reasonable efforts to form a
compensation committee and an audit committee of the Board of Directors as soon
as practicable following the effective date of this Agreement. Each committee
shall be comprised of at least two directors, provided that at least one
committee member of each committee shall be the Essex Nominee, the Investor
Nominee, the SLS Nominee or the Novo Nominee.

     2. COVENANTS OF THE PARTIES. The Company, the Common Holders and the
Investors agree to use their best efforts to ensure that the rights given to the
parties hereunder are effective and that each shall enjoy the benefits hereof.
Such efforts shall include the taking of all action from time to time
(including, without limitation, the voting of shares, execution of written
consents, the calling of special meetings, the removal of directors, the filling
of vacancies on the Board, the waiving of notice and attendance at meetings, the
amendment of the Company's by-laws and the like) necessary to maintain the
membership on the Board as required by Section 1. Neither the Company, the
Common Holders nor the Investors shall, by any voluntary action, avoid or seek
to avoid the observance or performance of any of the terms to be performed
hereunder by the Company, the Common Holders or the Investors, respectively, but
shall at all times in good faith assist in the carrying out of all of the
provisions of this Agreement and the protection of the respective rights of each
party hereto against impairment. The Company shall promptly reimburse all
reasonable expenses of each director incurred in attending any meeting of the
Board (or any committee thereof), whether in person or by remote access, and in
taking any other action requested in writing by the Company or the Board.

     3. SUCCESSOR AND ASSIGNS. This Agreement shall be binding upon and shall
inure to the benefit of the executors, administrators, legal representatives,
heirs, successors and assigns of the parties hereto; provided, however, that any
transferee of any shares of stock of the Company affected by this Agreement
shall be required, as a condition precedent to acquiring such shares, to first
agree in writing to be bound by all the terms and conditions of this Agreement
applicable to such transferee's transferor; and, provided further, that no
rights under this Agreement may be assigned apart from the related shares of the
Company's capital stock.

     4. LEGENDS. Each certificate representing either Common Stock or Series A
Preferred of the Company that is subject to this Agreement shall be endorsed by
the Company with the following legend:

          THE SHARES EVIDENCED HEREBY ARE SUBJECT TO A VOTING AGREEMENT (A COPY
          OF WHICH MAY BE OBTAINED FROM THE ISSUER), AND BY ACCEPTING ANY
          INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE
          DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF
          SAID VOTING AGREEMENT.

                                       -5-

<PAGE>

     5. OTHER RIGHTS. Except as provided by this Agreement, each Common Holder
and Investor shall exercise the full voting rights of a shareholder with respect
to their respective capital stock of the Company held.

     6. TERMINATION. This Agreement shall terminate upon the earlier of (i) the
consummation of the Company's Qualified IPO (as defined in the Series A
Agreement, (ii) the closing of a Change of Control (as defined in the Series A
Agreement), (iii) such time after the date hereof as there ceases to be any of
the Company's Series A Preferred outstanding, or (iv) the written agreement of
the parties required to amend this Agreement as set forth in Section 7.

     7. AMENDMENTS AND WAIVERS. Any term hereof may be amended and the
observance of any term hereof may be waived (either generally or in a particular
instance and either retroactively or prospectively) only with the written
consent of (i) the Company, (ii) the holders of a majority of the shares of the
Company's Series A Preferred then held by the Investors (which majority must
include Essex, SLS or Novo, as the case may be, to the extent any such amendment
or waiver adversely effects Essex's, SLS's or Novo's right to nominate or remove
any Essex Nominee, SLS Nominee or Novo Nominee, respectively) and (iii) the
holders of a majority of the shares of the Company's Common Stock then held by
the Common Holders. Any amendment or waiver so effected shall be binding upon
the Company, all of the Common Holders and all of the Investors and their
respective successors and permitted assigns.

     8. ENTIRE AGREEMENT; AMENDMENT OF PRIOR AGREEMENT. This Agreement
constitutes the entire agreement among the parties with regard to the subject
hereto and this Agreement supersedes any and all prior negotiations,
correspondence, understandings and agreements among the parties respecting the
subject matter hereof.

     9. SEVERABILITY. Whenever possible, each provision of this Agreement shall
be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement shall be held to be prohibited by or
invalid under applicable law, such provision shall be ineffective only to the
extent of such prohibition or invalidity, without invalidating the remainder of
such provision or the remaining provisions of this Agreement.

     10. GOVERNING LAW; JURISDICTION; VENUE; NO JURY TRIAL. This Agreement shall
be governed by and construed in accordance with the laws of the State of
Washington and the laws of the United States applicable therein (in each case
without giving effect to any choice or conflict of laws provision or rule that
would cause the application of the laws of any other jurisdiction) and shall be
treated in all respects as a Washington contract. Any action, suit or proceeding
arising out of or relating to this Agreement shall be brought in the state
courts of the State of Washington located in King County, or, if it has or can
acquire jurisdiction, any Federal court located in such State and County, and
EACH OF THE PARTIES HERETO, AFTER CONSULTING WITH OR HAVING HAD THE OPPORTUNITY
TO CONSULT WITH COUNSEL, HEREBY KNOWINGLY, VOLUNTARILY, INTENTIONALLY AND
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS AND WAIVES
TRIAL BY JURY, IN EACH CASE IN CONNECTION WITH ANY ACTION, SUIT OR PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT. Each of the parties hereto hereby
irrevocably and unconditionally waives any objection to the laying of venue of
any action, suit or proceeding arising out of or relating to this Agreement or
the

                                       -6-

<PAGE>

transactions contemplated hereby in the courts of the State of Washington or the
United States of America, in each case located in King County, and hereby
further irrevocably and unconditionally waives and agrees not to plead or claim
in any such court that any such matter brought in any such court has been
brought in an inconvenient forum.

     11. NOTICES. All notices, requests, consents, and other communications
under this Agreement shall be in writing and shall be deemed delivered (a) three
business days after being sent by registered or certified mail, return receipt
requested, postage prepaid, (b) one business day after being sent via a
reputable nationwide overnight courier service guaranteeing next business day
delivery or (c) upon delivery when sent by facsimile (with confirmation of
receipt), in each case to the intended recipient at the address indicated for
such party on the signature page or Schedules hereto, as applicable, or at such
other address as such party may designate by ten (10) days advance written
notice to the other parties.

     12. EQUITABLE REMEDIES. The Company, the Common Holders and the Investors
each acknowledge and agree that the legal remedies available to each party in
the event any party violates the covenants and agreements made in this Agreement
would be inadequate and that each party shall be entitled, without posting any
bond or other security, to temporary, preliminary, and permanent injunctive
relief, specific performance and other equitable remedies in the event of such a
violation, in addition to any other remedies which such party may have at law or
in equity.

     13. COUNTERPARTS. This Agreement may be executed in any number
counterparts, including by facsimile copy, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument.

               [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.]

                                       -7-

<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Second Amended and
Restated Voting Agreement effective as of the day and year hereinabove first
written.

THE COMPANY:                            LIGHT SCIENCES ONCOLOGY, INC.

                                        /s/ Llew Keltner
                                        ----------------------------------------
                                        By: Llew Keltner
                                        Its: Chief Executive Officer

                                        Address:
                                                 -------------------------------
                                        Fax No:
                                                --------------------------------

COMMON HOLDERS:

                                        LIGHT SCIENCES CORPORATION

                                        /s/ Albert Luderer
                                        ----------------------------------------
                                        By: Albert Luderer
                                        Its: Chief Executive Officer

INVESTORS:

                                        ESSEX WOODLANDS HEALTH
                                        VENTURES FUND VI, L.P.

                                        By: Essex Woodlands Health Ventures VI,
                                            L.P.
                                        Its: General Partner

                                        By: Essex Woodlands Health Ventures VI,
                                            L.L.C.
                                        Its: General Partner

                                        By: /s/ Jeff Himawan
                                            ------------------------------------
                                            Dr. Jeff Himawan, Managing Director

                                        ADAMS STREET V, L.P.

                                        By: Adams Street Partners, LLC
                                        Its: General Partner

                                        By: /s/ Craig Taylor
                                            ------------------------------------
                                            Craig S. Taylor, Ph.D., Partner
<PAGE>

INVESTORS:

                                        CHINA DEVELOPMENT
                                        INDUSTRIAL BANK, INC.

                                        By: /s/ Hsing-Ning Yu
                                            ------------------------------------
                                        Its: Director

                                        /s/ Edward Avedisian
                                        ----------------------------------------
                                        EDWARD AVEDISIAN

                                        /s/ Hsiu-Chuan Lee
                                        ----------------------------------------
                                        HSIU-CHUAN LEE

                                        /s/ Craig Watjen
                                        ----------------------------------------
                                        CRAIG M. WATJEN

INVESTORS:

                                        JOHNSON & JOHNSON DEVELOPMENT
                                        CORPORATION

                                        /s/ Roger Guidi
                                        ----------------------------------------
                                        Roger Guidi, Vice President

<PAGE>

INVESTORS:

                                        SCANDINAVIAN LIFE SCIENCE VENTURE TWO KB

                                        By: /s/ Martin Olin Andersen
                                            ------------------------------------
                                        Its: Senior Partner

                                        MEDICON VALLEY CAPITAL TWO KB

                                        By: /s/ Martin Olin Andersen
                                            ------------------------------------
                                        Its: Senior Partner

                                        MEDICON VALLEY CAPITAL II K/S

                                        By: /s/ Martin Olin Andersen
                                            ------------------------------------
                                        Its: Senior Partner

<PAGE>

INVESTORS:

                                        NOVO A/S

                                        By: /s/ Henrik Gurtler
                                            ------------------------------------
                                            Henrik Gurtler
                                            Chief Executive Officer

                                        NSV PARTNERS INSTITUTIONAL, LP

                                        By: New Science Ventures, LLC
                                        Its: General Partner

                                        By: /s/ Thomas J. A. Lavin
                                            ------------------------------------
                                        Its: Chief Financial Officer

                                        NSV PARTNERS IX (LSO), LP

                                        By: New Science Ventures, LLC
                                        Its: General Partner

                                        By: /s/ Thomas J. A. Lavin
                                            ------------------------------------
                                        Its: Chief Financial Officer

                                        /s/ Vincent Lum
                                        ----------------------------------------
                                        VINCENT LUM

<PAGE>

                                   SCHEDULE I

                                 COMMON HOLDERS

<TABLE>
<CAPTION>
Common Holder Name and Address   Shares of Common Stock Held
------------------------------   ---------------------------
<S>                              <C>
Light Sciences Corporation                 7,743,040
34931 SE Douglas Street
Suite 200
Snoqualmie, WA 98065

                                           7,743,040

TOTAL
</TABLE>

<PAGE>

                                   SCHEDULE II

                                    INVESTORS

<TABLE>
<CAPTION>
Investor Name and Address                                    Series A Shares Held
-------------------------                                    --------------------
<S>                                                          <C>
ESSEX WOODLANDS HEALTH VENTURES FUND VI, L.P.                     4,000,000
435 Tasso Street, Suite 305
Palo Alto, CA 94301
Attn: Dr. Jeff Himawan
Fax: (419) 821-4765

with a copy to (which shall not constitute notice):
Baker & McKenzie LLP
130 E. Randolph Drive
Chicago, IL 60601
Attn: Bruce Zivian, Esq.
Fax: (312) 698-2469

CRAIG WATJEN                                                      1,424,989
14571 Southeast 51st St.
Bellevue, Wa. 98006
Fax: (425) 649-9898

ADAMS STREET V, L.P.                                              1,000,000
1 N Wacker Drive, Suite 2200
Chicago, IL 60606
Attn: Craig Taylor
Fax:

CHINA DEVELOPMENT INDUSTRIAL BANK, INC.                             400,000
No. 125, Nanking East Road Section 5,
Taipei 105, Taiwan
Attn: Ita Lu
Fax: +886.2.2746.7612

EDWARD AVEDISIAN                                                    200,000
12 Sanderson Road
Lexington, MA 02420
Fax: (781) 860 0282

HSIU-CHUAN LEE                                                      20,000
F3, No. 28,  Chung Shan North Road,
Section 3, Lane 55,
Taipei 104 Taiwan
Fax:
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
Investor Name and Address                                    Series A Shares Held
-------------------------                                    --------------------
<S>                                                          <C>
JOHNSON & JOHNSON DEVELOPMENT CORPORATION                           800,000
410 George Street
New Brunswick, NJ 08901
Attn: Roger Guidi and Kathy Horvath
Fax: (732) 247-5309

with a copy to (which shall not constitute notice):
Johnson & Johnson
Law Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Attn: Manish Yadav
Fax: (732) 524-5823

and a further copy to (which shall not constitute notice):
Ropes & Gray LLP
45 Rockefeller Plaza
New York, NY 10111
Attn:  Kristopher Brown
Fax: (212) 841-5725

SCANDINAVIAN LIFE SCIENCE VENTURE TWO KB                          1,645,404
Birger Jarlsgaten 10
SE-114 34 Stockholm
Sweden
Attn: Martin Olin Andersen

MEDICON VALLEY CAPITAL TWO KB                                       463,064
Birger Jarlsgaten 10
SE-114 34 Stockholm
Sweden
Attn: Martin Olin Andersen

MEDICON VALLEY CAPITAL II K/S                                       231,532
Islands Brygge 57, st. th.
DK-2300 Copenhagen
Denmark
Attn: Martin Olin Andersen

NOVO A/S                                                          2,000,000
Krogshoejvej 41
2880 Bagsvaerd
Denmark

Attn: Henrik Gurtler
Fax: +45 4442 1440

NSV PARTNERS INSTITUTIONAL, LP                                      708,000
New Science Ventures, LLC
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
Investor Name and Address                                    Series A Shares Held
-------------------------                                    --------------------
<S>                                                          <C>
645 Madison Ave.- 20th floor
New York, NY 10022
Attn: Thomas JA Lavin, CFO

NSV PARTNERS IX (LSO), LP                                           532,000
New Science Ventures, LLC
645 Madison Ave.- 20th floor
New York, NY 10022
Attn: Thomas JA Lavin, CFO

VINCENT LUM                                                           5,000
1257 West 47th Avenue
Vancouver, BC  V6M 2L5
Canada

TOTAL                                                            13,429,989
</TABLE>

<PAGE>

                                    EXHIBIT A

                        FORM OF INDEMNIFICATION AGREEMENT<PAGE>

                                                                   Exhibit 10.21

                          LIGHT SCIENCES ONCOLOGY, INC.

                  RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT

     THIS RIGHT OF FIRST REFUSAL AND CO SALE AGREEMENT, entered into as of
October 6, 2005, by and among Light Sciences Oncology, Inc., a Washington
corporation (the "Company"), Light Sciences Corporation, a Washington
corporation ("LSC"), each of the persons and entities on Schedule I attached
hereto (the "Founders"), each of the persons and entities on Schedule II
attached hereto (the "Investors"), and each of the persons and entities on
Schedule III attached hereto (the "LSC Holders").

                                   WITNESSETH:

     WHEREAS, the Company and Investors are parties to that certain Series A
Preferred Stock Purchase Agreement of even date herewith (the "Purchase
Agreement"), pursuant to which Investors are purchasing that number of shares of
the Company's Series A Preferred Stock (the "Series A Preferred Stock") as set
forth beside such Investor's name on Schedule II hereto; and

     WHEREAS, each Founder is the beneficial owner of shares of Common Stock of
the Company as set forth beside such Founder's name on Schedule I hereto; and

     WHEREAS, each LSC Holder is the beneficial owner of shares of Common Stock
and/or Preferred Stock of LSC as set forth beside such LSC Holder's name on
Schedule III hereto; and

     WHEREAS, the Founders and the LSC Holders wish to provide further
inducement to the Investors to purchase the Series A Preferred Stock by agreeing
to grant Investors certain rights and restrictions with respect to the shares of
stock owned or subsequently acquired by such Founders and such LSC Holders, all
on the terms and conditions set forth in this Agreement:

     NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
promises set forth in this Agreement and for other consideration, the receipt
and adequacy of which is hereby acknowledged, the Company, LSC, Founders, LSC
Holders and Investors agree as follows:

     1. Restrictions on Transfer of Shares by Founders. Except as otherwise
provided in this Agreement, each Founder will not sell, assign, transfer,
pledge, hypothecate, or otherwise encumber or dispose of in any way, all or any
part of or any interest in the Stock (as hereinafter defined) now or hereafter
owned or held by such Founder. Any sale, assignment, transfer, pledge,
hypothecation or other encumbrance or disposition of the Stock by a Founder not
made in conformance with this Agreement shall be null and void, shall not be
recorded on the books of the Company and shall not be recognized by the Company.

     2. Definitions.

     (a) "Available Undersubscription Amount" means the difference between the
total of all Basic Amounts available for purchase pursuant to Section 9(a), and
the Basic Amounts subscribed for pursuant to such Section.

<PAGE>

     (b) "Basic Amount" means for purposes of Section 9(a), and with respect to
a particular Investor having preemptive rights under such Section, his, her or
its pro rata portion of the Offered Securities, determined by multiplying the
Offered Securities by the quotient obtained by dividing the aggregate number of
shares of Common Stock then held by such Investor (giving effect to the
conversion or exercise into Common Stock of all convertible or exercisable
securities then held by such Investor) by the total number of shares of Common
Stock then outstanding (giving effect to the conversion or exercise into Common
Stock of all convertible or exercisable securities then outstanding); provided
that any shares of Common Stock (other than shares of common stock into which
shares of Preferred Stock have converted) held by a Founder who is also a holder
of Preferred Stock shall be excluded from the numerator.

     (c) "Common Stock" means the Company's outstanding Common Stock and shares
of Common Stock issued or issuable upon conversion of the Company's outstanding
Series A Preferred Stock.

     (d) "Industry Operating Company" means any entity that has substantial
operations in the business of developing or commercializing medical devices,
medical diagnostic products or drugs directly or through affiliates.

     (e) "LSC Corporate Transaction" means a LSC Change of Control in which the
acquiring party is an Industry Operating Company.

     (f) "LSC Change of Control" means any of the following:

          (i) any consolidation or merger of LSC with or into any other
     corporation or other entity, or any other corporate reorganization, in
     which the shareholders of LSC immediately prior to such consolidation,
     merger or reorganization, own less than 50% of LSC's voting power
     immediately after such consolidation, merger or reorganization;

          (ii) any transaction or series of related transactions in which in
     excess of 50% of LSC's voting power is transferred to a party or parties
     who were not shareholders or affiliates of shareholders prior to such
     transfer; or

          (iii) a sale, lease, transfer or other disposition (including, without
     limitation, by an exclusive license of all or substantially all of its
     rights in the material intellectual property of LSC for a term of at least
     all or substantially all of the effective period of the material patents
     included therein) of all or substantially all of the assets of LSC.

     (g) "LSC Stock" means shares of LSC's Common Stock or Preferred Stock now
owned or subsequently acquired by a LSC Holder.

     (h) "LSC Subsidiary Investor" means any purchaser of Series A preferred
stock in any subsidiary of LSC, including the Investors, who continues to hold
such shares.

     (i) "Notice of Acceptance" means a written notice from an Investor to the
Company containing the information specified in Section 9(a).

                                       2

<PAGE>

     (j) "Offered Securities" means (i) any shares of Common Stock, (ii) any
other equity securities of the Company, including, without limitation, shares of
preferred stock, (iii) any option, warrant or other right to subscribe for,
purchase or otherwise acquire any equity securities of the Company or (iv) any
debt securities convertible into capital stock of the Company.

     (k) "Preferred Stock" means the Company's outstanding Series A Preferred
Stock.

     (l) "Refused Securities" means those Offered Securities as to which a
Notice of Acceptance has not been given by the Investors pursuant to Section
9(a).

     (m) "Rights Agreement" means the Investors Rights Agreement of even date
herewith among the Company and the other parties specified therein.

     (n) "Stock" means shares of the Company's Common Stock or Preferred Stock
now owned or subsequently acquired by a Founder; provided that shares of
Preferred Stock purchased by a Founder pursuant to the Purchase Agreement shall
not be considered "Stock".

     (o) "Undersubscription Amount" means for purposes of Section 9(a), and with
respect to a particular Investor having preemptive rights under such Section,
any additional portion of the Offered Securities attributable to the Basic
Amounts of other Investors having preemptive rights under such Section as such
Investor indicates it will purchase or acquire should the other Investors
subscribe for less than their Basic Amounts.

     3. Rights of First Refusal.

     (a) Transfer Notice. If at any time a Founder (the "Selling Founder")
proposes to transfer Stock to one or more third parties pursuant to an
understanding or agreement with such third parties (a "Founder Transfer"), then
the Selling Founder shall give the Company and each Investor written notice of
the Selling Founder's intention to make the Founder Transfer (the "Founder
Transfer Notice"), which Founder Transfer Notice shall include (i) a description
of the Stock to be transferred ("Offered Common Shares"), (ii) the identity of
the prospective transferee(s) and (iii) the consideration and the material terms
and conditions upon which the proposed Founder Transfer is to be made. The
Founder Transfer Notice shall certify that the Selling Founder has received a
firm offer from the prospective transferee(s) and in good faith believes a
binding agreement for the Founder Transfer is obtainable on the terms set forth
in the Founder Transfer Notice. The Founder Transfer Notice shall also include a
copy of any written proposal, term sheet or letter of intent or other agreement
relating to the proposed Founder Transfer. The Founders severally agree that
they shall not enter into any understanding or agreement with respect to a
Founder Transfer subject to this Section 3 in which the Founder would receive
any consideration in any form other than cash, an unsecured promissory note, or
a combination of the foregoing.

     (b) Company Option. The Company shall have a right of first refusal (the
"Company's Right of First Refusal") to purchase, all but not less than all of,
the Offered Common Shares at the same price and subject to the same material
terms and conditions as described in the Founder Transfer Notice, if the Company
gives written notice of the exercise of such right to the Selling Founder and
the Investors within thirty (30) days (the "Company's

                                       3

<PAGE>

Refusal Period") from the receipt of the Founder Transfer Notice. If the Company
does not intend to exercise the Company's right of first refusal in full or if
the Company is not lawfully able to repurchase the Offered Common Shares, the
Company shall send written notice thereof (the "Company's Expiration Notice") to
the Selling Founder and to the Investors at least fifteen (15) days before the
expiration of the Company's Refusal Period. If the Company gives the Selling
Founder notice that it desires to purchase the Offered Common Shares, then
payment for the Offered Common Shares shall be by certified bank check or wire
transfer, against delivery of the Offered Common Shares to be purchased at a
place agreed upon between the parties and at the time of the scheduled closing
therefor, which shall be no later than forty five (45) days after the Company's
receipt of the Founder Transfer Notice, unless the Founder Transfer Notice
contemplated a later closing with the prospective third party transferee(s). The
Company may not assign its rights under this paragraph.

     (c) Series A Holders' Option. If the Company does not exercise its right of
first refusal in full, the Investors holding Series A Preferred Stock shall have
an option for a period of thirty (30) days from receipt of the Founder Transfer
Notice from the Selling Founder set forth in Section 3(a) hereof to elect to
purchase their respective pro rata shares of the Offered Common Shares at the
same price and subject to the same material terms and conditions as described in
the Founder Transfer Notice. Each such Investor may exercise such purchase
option and, thereby, purchase all or any portion of its pro rata share (with any
reallotments as provided below) of the Offered Common Shares, by notifying the
Selling Founder and the Company in writing, before expiration of the thirty (30)
day period as to the number of such shares which it wishes to purchase
(including any reallotment). Each such Investor's pro rata share of the Offered
Common Shares shall be a fraction of the Offered Common Shares, of which the
number of shares of Common Stock (including shares of Common Stock issuable upon
conversion of Preferred Shares) owned by such Investor on the date of the
Founder Transfer Notice shall be the numerator and the total number of shares of
Common Stock (including shares of Common Stock issuable upon conversion of
Preferred Shares) held by all Investors holding Series A Preferred Stock on the
date of the Founder Transfer Notice shall be the denominator. Each such Investor
shall have a right of reallotment such that, if any other such Investor fails to
exercise the right to purchase its full pro rata share of the Offered Common
Shares, the other participating Investors may exercise an additional right to
purchase, on a pro rata basis, the Offered Common Shares not previously
purchased. If an Investor gives the Selling Founder notice that it desires to
purchase its pro rata share of the Offered Common Shares and, as the case may
be, its reallotment, then payment for the Offered Common Shares shall be by
certified bank check or wire transfer, against delivery of the Offered Common
Shares to be purchased at a place agreed upon between the parties and at the
time of the scheduled closing therefor, which shall be no later than forty five
(45) days after the Investor's receipt of the Founder Transfer Notice, unless
the Founder Transfer Notice contemplated a later closing with the prospective
third party transferee(s).

     4. Right of Co Sale.

     (a) To the extent the Investors do not exercise their respective rights of
refusal as to all of the Offered Common Shares pursuant to Section 3 hereof,
then each Investor holding Series A Preferred Stock that did not exercise its
right of refusal which notifies the Selling Founder in writing within thirty
(30) days after receipt of the Founder Transfer Notice referred to in Section
3(a) hereof (a "Selling Investor" for purposes of this Section 4), shall have
the right to

                                       4

<PAGE>

participate in such sale of Stock on the same terms and conditions as specified
in the Founder Transfer Notice. Such Selling Investor's notice to the Selling
Founder shall indicate the number of shares of Preferred Stock (or Common Stock
issued or issuable upon conversion thereof) the Selling Investor wishes to sell
under its right to participate. To the extent one or more of the Investors
exercise such right of participation in accordance with the terms and conditions
set forth below, the number of shares of Stock that the Founder may sell in the
Founder Transfer shall be correspondingly reduced.

     (b) Each Selling Investor may sell all or any part of that number of shares
of Preferred Stock (or Common Stock issued or issuable upon conversion thereof)
equal to the product obtained by multiplying (i) the aggregate number of shares
of Stock covered by the Transfer Notice by (ii) a fraction, the numerator of
which is the number of shares of Common Stock (including shares of Common Stock
issuable upon conversion of Preferred Shares) owned by the Selling Investor on
the date of the Founder Transfer Notice and the denominator of which is the
total number of shares of Common Stock (including shares of Common Stock
issuable upon conversion of Preferred Shares) owned by the Selling Founder and
all of the Selling Investors on the date of the Founder Transfer Notice.

     (c) Each Selling Investor shall effect its participation in the sale by
promptly delivering to the Selling Founder for transfer to the prospective
purchaser one or more certificates, properly endorsed for transfer, which
represent:

          (i) number of shares of Common Stock which such Selling Investor
     elects to sell; or

          (ii) the type and number of shares of Preferred Stock which are at
     such time convertible into the number of shares of Common Stock which such
     Selling Investor elects to sell; provided, however, that if the prospective
     third party purchaser objects to the delivery of Preferred Stock in lieu of
     Common Stock, such Selling Investor shall convert such Preferred Stock into
     Common Stock and deliver Common Stock as provided in this Section 4. The
     Company agrees to make any such conversion concurrent with the actual
     transfer of such shares to the purchaser and contingent on such transfer.

     (d) The stock certificate or certificates that the Selling Investor
delivers to the Selling Founder pursuant to this Section 4(d) shall be
transferred to the prospective purchaser in consummation of the sale of the
Preferred Stock (or Common Stock issued or issuable upon conversion thereof)
pursuant to the terms and conditions specified in the Founder Transfer Notice,
and the Selling Founder shall concurrently therewith remit to such Selling
Investor that portion of the sale proceeds to which such Selling Investor is
entitled by reason of its participation in such sale. To the extent that any
prospective purchaser or purchasers prohibits such assignment or otherwise
refuses to purchase shares or other securities from a Selling Investor
exercising its rights of co sale hereunder, the Selling Founder shall not sell
to such prospective purchaser or purchasers any Stock unless and until,
simultaneously with such sale, the Selling Founder shall purchase such shares or
other securities from such Selling Investor for the same consideration and on
the same terms and conditions as the proposed transfer described in the Founder
Transfer Notice.

                                       5

<PAGE>

     5. Non Exercise of Rights. To the extent that the Investors have not
exercised their rights to purchase the Offered Common Shares within the time
period specified in Section 3 hereof and the Investors have not exercised their
rights to participate in the sale of the Offered Common Shares within the time
period specified in Section 4 hereof, the Selling Founder shall have a period of
sixty (60) days from the expiration of such rights in which to sell the
remaining Offered Common Shares, as the case may be, upon terms and conditions
(including the purchase price) no more favorable than those specified in the
Founder Transfer Notice to the third party transferee(s) identified in the
Founder Transfer Notice. The third party transferee(s) shall acquire the Offered
Common Shares free and clear of subsequent rights of first refusal and co sale
rights under this Agreement. In the event the Selling Founder does not
consummate the sale or disposition of the Offered Common Shares within the sixty
(60) day period from the expiration of these rights, the Investors' first
refusal rights and co sale rights shall continue to be applicable to any
subsequent disposition of the Offered Common Shares by the Selling Founder until
such right lapses in accordance with the terms of this Agreement. Furthermore,
the exercise or non exercise of the rights of the Investors under this Section 5
to purchase Stock from the Selling Founder or participate in sales of Stock by
the Selling Founder shall not adversely affect their rights to make subsequent
purchases from the Selling Founder of Stock or subsequently participate in sales
of Stock by the Selling Founder.

     6. Exempt Transfers.

     (a) Notwithstanding the foregoing, the provisions of Sections 3 and 4
hereof shall not pertain or apply to (i) any transfer by a Founder to the
ancestors, descendants, siblings or spouse of such Founder, or to trusts solely
for the benefit of such persons or such Founder, (ii) any transfer to a
Founder's estate, heirs administrators or executors upon the death of Founder,
or (iii) any bona fide gift to a not-for-profit entity; provided, however, that
the Selling Founder shall inform the Investors of such transfer prior to
effecting it and the transferee or donee shall furnish the Investors with a
written agreement to be bound by and comply with all provisions of this
Agreement (including Sections 3 and 4 hereof) and provided, further, that no
Selling Founder may gift more than 10% of his Stock pursuant to clause (iii)
above in any calendar year unless the Selling Founder has retained all voting
rights with respect to such Stock. Such transferred Stock shall remain "Stock"
hereunder, and such transferee shall be treated as a "Founder" for purposes of
this Agreement. In addition, the provisions of Sections 3 and 4 shall not apply
to any repurchase of Stock pursuant to a written agreement between the Company
and a Founder approved by the Board of Directors and providing for the right of
such repurchase.

     (b) Notwithstanding the foregoing, the provisions of Sections 3 and 4
hereof shall not apply to (i) the sale of any Stock to the public pursuant to a
registration statement filed with, and declared effective by, the Securities and
Exchange Commission under the Securities Act of 1933, as amended (the
"Securities Act") or (ii) the transfer of shares of Stock to a Founder's
shareholders, limited partners or members (provided that in the case of clause
(ii) each transferee of three percent (3%) or more of the shares of Stock so
transferred becomes party to this Agreement and bound by the terms and
conditions of this Agreement as if such transferee were a "Founder" hereunder.
Such transferred Stock shall remain "Stock" hereunder, and such transferee shall
be treated as a "Founder" for purposes of this Agreement).

     7. Prohibited Transfers.

                                       6

<PAGE>

     (a) In the event a Selling Founder should sell any Stock in contravention
of the co-sale rights of the Investors under Section 4 hereof (a "Prohibited
Transfer"), the Investors, in addition to such other remedies as may be
available at law, in equity or hereunder, shall have the put option provided
below, and such Selling Founder shall be bound by the applicable provisions of
such option.

     (b) In the event of a Prohibited Transfer, each Investor shall have the
right to sell to such Selling Founder the type and number of shares of Preferred
Stock (or Common Stock issued or issuable upon conversion thereof) equal to the
number of shares each Investor would have been entitled to transfer to the third
party transferee(s) under Section 4 hereof had the Prohibited Transfer been
effected pursuant to and in compliance with the terms hereof. Such sale shall be
made on the following terms and conditions:

          (i) The price per share at which the shares are to be sold to such
     Selling Founder shall be equal to the price at which such shares would have
     been sold to third party pursuant to Section 4 hereof had the Prohibited
     Transfer been effected pursuant to and in compliance with the terms hereof.
     Such Selling Founder shall also reimburse each Investor for any and all
     fees and expense, including legal fees and expenses, incurred pursuant to
     the exercise or the attempted exercise of the Investor's rights under
     Section 3 or 4 hereof.

          (ii) Within ninety (90) days after the later of the dates on which the
     Investor (A) received notice of the Prohibited Transfer or (B) otherwise
     became aware of the Prohibited Transfer, each Investor shall, if exercising
     the option created hereby, deliver to such Selling Founder the certificate
     or certificates representing shares to be sold, each certificate to be
     properly endorsed for transfer.

          (iii) Such Selling Founder shall, upon receipt of the certificate or
     certificates for the shares to be sold by an Investor, pursuant to this
     Section 7, pay the aggregate purchase price therefor and the amount of
     reimbursable fees and expenses, as specified in Section 7(b)(i) hereof, in
     cash or by other means acceptable to the Investor.

          (iv) Notwithstanding the foregoing, any attempt by the Selling Founder
     to transfer Stock in violation of Section 3 or 4 hereof shall be void and
     the Company agrees it will not effect such a transfer nor will it treat any
     alleged transferee(s) as the holder of such shares without the written
     consent of a majority in interest of the Investors.

     8. Restrictions on Transfer of Shares by LSC Holders.

     (a) Except as otherwise provided in this Agreement, each LSC Holder will
not sell, assign, transfer, pledge, hypothecate, or otherwise encumber or
dispose of in any way, all or any part of or any interest in the LSC Stock now
or hereafter owned or held by such LSC Holder. Any sale, assignment, transfer,
pledge, hypothecation or other encumbrance or disposition of the LSC Stock by a
LSC Holder not made in conformance with this Agreement shall be null and void,
shall not be recorded on the books of LSC and shall not be recognized by LSC.

     (b) If at any time a LSC Holder (the "Selling LSC Holder") proposes to
transfer LSC Stock to one or more third parties pursuant to an understanding or
agreement with such third

                                       7

<PAGE>

parties (a "LSC Holder Transfer"), then the Selling LSC Holder shall give LSC
and each LSC Subsidiary Investor written notice of the Selling LSC Holder's
intention to make the LSC Holder Transfer (the "LSC Holder Transfer Notice"),
which LSC Holder Transfer Notice shall include (i) a description of the LSC
Stock to be transferred ("Offered LSC Common Shares"), (ii) the identity of the
prospective transferee(s) and (iii) the consideration and the material terms and
conditions upon which the proposed LSC Holder Transfer is to be made. The LSC
Holder Transfer Notice shall certify that the Selling LSC Holder has received a
firm offer from the prospective transferee(s) and in good faith believes a
binding agreement for the LSC Holder Transfer is obtainable on the terms set
forth in the LSC Holder Transfer Notice. The LSC Holder Transfer Notice shall
also include a copy of any written proposal, term sheet or letter of intent or
other agreement relating to the proposed LSC Holder Transfer.

     (c) Each LSC Subsidiary Investor shall have an option for a period of
thirty (30) days from receipt of the LSC Holder Transfer Notice from the Selling
LSC Holder set forth in Section 8(a) hereof to elect to purchase their
respective pro rata shares of the Offered LSC Common Shares at the same price
and subject to the same material terms and conditions as described in the LSC
Holder Transfer Notice. The purchase price for the Offered LSC Common Shares to
be purchased by a LSC Subsidiary Investor exercising its right of first refusal
under this Agreement shall be the offered price set forth in the LSC Holder
Transfer Notice and shall be payable as set forth in subsection (e) below.

     (d) In the event that some or all of the consideration to be received by a
Selling LSC Holder is to be made in a form other than cash or cash equivalents,
the price per share shall be determined as follows. The LSC Subsidiary Investors
shall be entitled to purchase any Offered LSC Common Shares at the price set
forth in the LSC Holder Transfer Notice, except that they may pay in cash the
fair market value of any such non-cash consideration, with such fair market
value measured in good faith by the Board of Directors of LSC, provided that (x)
if a majority in interest of the LSC Subsidiary Investors exercising their
purchase option with respect to such Offered LSC Common Shares dispute such
valuation in writing to LSC, then LSC shall engage an independent third party
valuation expert who shall determine whether the valuation proposed by the LSC
Board or that proposed by such majority in interest is closer to the actual fair
market value, and such closest valuation shall be treated as the fair market
value hereunder (it being agreed the expert may only choose between the two
competing valuations, and not select any other value), with the fees and
expenses of the expert borne by the party or parties whose proposed valuation is
the valuation not selected by the expert (provided that if the LSC Subsidiary
Investors are responsible for the expert's fees and expenses, such fees and
expenses will be borne by the LSC Subsidiary Investors who have elected to
participate in the proposed transfer pro rata on the basis of the number of
Offered LSC Common Shares to be purchased by such LSC Subsidiary Investor); and
(y) if any securities are to be received by the Selling LSC Holder, the fair
market value of such securities shall be determined as follows:

          (i) for securities not subject to investment letter or other similar
     restrictions on free marketability covered by (ii) below:

               (A) if traded on a securities exchange or through the NASDAQ
National Market, the value shall be deemed to be the average of the closing
prices of the

                                       8

<PAGE>

securities on such quotation system over the thirty (30) day period ending three
(3) days prior to the closing;

               (B) if actively traded over-the-counter, the value shall be
deemed to be the average of the closing bid or sale prices (whichever is
applicable) over the thirty (30) day period ending three (3) days prior to the
closing; and

               (C) if there is no active public market, the value shall be the
fair market value thereof, as determined by the Board of Directors of LSC
(subject to the right of dispute and third party expert valuation specified
above).

          (ii) The method of valuation of securities subject to investment
     letter or other restrictions on free marketability (other than restrictions
     arising solely by virtue of a shareholder's status as an affiliate or
     former affiliate) shall be to make an appropriate discount from the market
     value determined as above in (i)(A), (B) or (C) to reflect the approximate
     fair market value thereof, as determined by the Board of Directors of LSC
     (subject to the right of dispute and third party expert valuation specified
     above).

If the time for the closing of the LSC Subsidiary Investors' purchase has
expired but for the determination of the value of the purchase price offered by
the prospective transferee(s), then such closing shall be held on or prior to
the fifth business day after such valuation shall have been finally determined
pursuant to this subsection.

     (e) Each such LSC Subsidiary Investor may exercise such purchase option
and, thereby, purchase some or all of its pro rata share (with any reallotments
as provided below) of the Offered LSC Common Shares, by notifying the Selling
LSC Holder and LSC in writing, before expiration of the thirty (30) day period
as to the number of such shares which it wishes to purchase (including any
reallotment); provided, however, that in the event that the LSC Holder Transfer
Notice pertains to the transfer of LSC Stock pursuant to a LSC Corporate
Transaction, then no LSC Subsidiary Investor shall be permitted to exercise its
right of first refusal pursuant to this Section 8 unless all of the Offered LSC
Common Shares shall be purchased by the LSC Subsidiary Investors. Each such LSC
Subsidiary Investor's pro rata share of the Offered LSC Common Shares shall be a
fraction of the Offered LSC Common Shares, of which the total purchase price of
all shares of Series A preferred stock of any LSC subsidiary (including the
Company) held by such LSC Subsidiary Investor on the date of the LSC Holder
Transfer Notice shall be the numerator, and the aggregate purchase price of all
shares of Series A preferred stock of any LSC subsidiary (including the Company)
held by all LSC Subsidiary Investors on the date of the LSC Holder Transfer
Notice shall be the denominator. Each such LSC Subsidiary Investor shall have a
right of reallotment such that, if any other such LSC Subsidiary Investor fails
to exercise the right to purchase its full pro rata share of the Offered LSC
Common Shares, the other participating LSC Subsidiary Investors may exercise an
additional right to purchase, on a pro rata basis (or such other basis as is
agreed between the LSC Subsidiary Investors exercising their option), the
Offered LSC Common Shares not previously purchased. If a LSC Subsidiary Investor
gives the Selling LSC Holder notice that it desires to purchase its pro rata
share of the Offered LSC Common Shares and, as the case may be, its reallotment,
then payment for the Offered LSC Common Shares shall be by certified bank check
or wire transfer, against delivery of the Offered LSC Common Shares to be
purchased at a place agreed upon between the parties

                                       9

<PAGE>

and at the time of the scheduled closing therefor, which shall be no later than
forty five (45) days after the LSC Subsidiary Investor's receipt of the LSC
Holder Transfer Notice, unless the LSC Holder Transfer Notice contemplated a
later closing with the prospective third party transferee(s).

     (f) To the extent that the LSC Subsidiary Investors have not exercised in
full their rights to purchase all of the Offered LSC Common Shares within the
time period specified in Section 8 hereof, the Selling LSC Holder shall have a
period of sixty (60) days from the expiration of such rights in which to sell
the remaining Offered LSC Common Shares upon terms and conditions (including the
purchase price) no more favorable than those specified in the LSC Holder
Transfer Notice to the third party transferee(s) identified in the LSC Holder
Transfer Notice. The third party transferee(s) shall acquire the Offered LSC
Shares free and clear of subsequent rights of first refusal under this
Agreement. In the event the Selling LSC Holder does not consummate the sale or
disposition of the Offered LSC Common Shares within the sixty (60) day period
from the expiration of these rights, the LSC Subsidiary Investors' first refusal
rights shall continue to be applicable to any subsequent disposition of the
Offered LSC Common Shares by the Selling LSC Holder until such right lapses in
accordance with the terms of this Agreement. Furthermore, the exercise or non
exercise of the rights of the LSC Subsidiary Investors under this Section 8 to
purchase LSC Stock from the Selling LSC Holder shall not adversely affect their
rights to make subsequent purchases from the Selling LSC Holder of LSC Stock.

     (g) Notwithstanding the foregoing, the provisions of Section 8 shall not
pertain or apply to (i) any transfer by a LSC Holder to the ancestors,
descendants, siblings or spouse of such LSC Holder, or to trusts solely for the
benefit of such persons or such LSC Holder, (ii) any transfer to a LSC Holder's
estate, heirs administrators or executors upon the death of a LSC Holder, or
(iii) any bona fide gift to a not-for-profit entity; provided, however, that the
Selling LSC Holder shall inform the LSC Subsidiary Investors of such transfer
prior to effecting it and the transferee or donee shall furnish the LSC
Subsidiary Investors with a written agreement to be bound by and comply with all
provisions of this Agreement and provided, further, that no Selling LSC Holder
may gift more than 10% of his LSC Stock pursuant to clause (iii) above in any
calendar year unless the Selling LSC Holder has retained all voting rights with
respect to such LSC Stock. Such transferred LSC Stock shall remain "LSC Stock"
hereunder, and such transferee shall be treated as a "LSC Holder" for purposes
of this Agreement. In addition, the provisions of Section 8 shall not apply to
any repurchase of LSC Stock pursuant to a written agreement between the Company
and a LSC Holder approved by the Board of Directors of LSC and providing for the
right of such repurchase.

     (h) Notwithstanding the foregoing, the obligations of the LSC Holders, and
the rights of the LSC Subsidiary Investors, under this Section 8 shall terminate
upon the earlier of (i) immediately prior to the effective time of the initial
public offering of LSC common stock to the general public pursuant to a
registration statement filed with the Securities and Exchange Commission under
the Securities Act, (ii) immediately after the closing of a LSC Change of
Control made in compliance with the applicable provisions of this Agreement, if
any, and (iii) at such time when LSC no longer holds more than five percent (5%)
of the outstanding shares of the Company on an as-converted basis.

                                       10

<PAGE>

     9. Participation Rights. The Company shall not issue, sell or exchange,
agree to issue, sell or exchange, or reserve or set aside for issuance, sale or
exchange, any Offered Securities, unless in each such case the Company shall
have complied with this Section 9. The Company shall deliver to each Investor an
offer (an "Offer"), which shall (i) identify and describe the Offered
Securities, (ii) describe the price and other terms upon which they are to be
issued, sold or exchanged, and the number or amount of the Offered Securities to
be issued, sold or exchanged, and (iii) identify the persons or entities to
which or with which the Offered Securities are to be offered, issued, sold or
exchanged. The Offer by its terms shall remain open and irrevocable for at least
30 days.

     (a) Each Investor holding at least 600,000 shares (as adjusted for any
stock dividends, combinations, splits, recapitalizations and the like) of Series
A Preferred Stock (a "Major Investor") shall have the right, for a period of 30
days following delivery of the Offer, to purchase or acquire, at a price and
upon the other terms specified in the Offer, such Major Investor's Basic Amount
and Undersubscription Amount, if any. To accept an Offer, in whole or in part,
such a Major Investor must deliver a Notice of Acceptance to the Company prior
to the end of the 30-day period of the Offer, setting forth the portion of the
Basic Amount that such Major Investor elects to purchase and, if such Major
Investor shall elect to purchase all of its Basic Amount, the Undersubscription
Amount (if any) that such Major Investor elects to purchase. If the Basic
Amounts subscribed for by all Major Investors under this Section 9(a) are less
than the total of all Basic Amounts available for purchase, then each Major
Investor who has set forth an Undersubscription Amount in its Notice of
Acceptance shall be entitled to purchase, in addition to the Basic Amounts
subscribed for, the Undersubscription Amount it has subscribed for; provided,
however, that should the Undersubscription Amounts subscribed for exceed the
Available Undersubscription Amount, each Major Investor who has subscribed for
any Undersubscription Amount shall be entitled to purchase only that portion of
the Available Undersubscription Amount as the Undersubscription Amount
subscribed for by such Major Investor bears to the total Undersubscription
Amounts subscribed for by all Major Investors, subject to rounding by the Board
of Directors to the extent it reasonably deems necessary.

     (b) The Company shall have 90 days from the expiration of the 30-day period
set forth above to issue, sell or exchange all or any part of the Refused
Securities, but only to the offerees or purchasers described in the Offer and
only upon terms and conditions (including, without limitation, unit prices and
interest rates) which are not on the whole more favorable to the acquiring
person or persons or on the whole less favorable to the Company than those set
forth in the Offer.

     (c) The purchase and sale of the Offered Securities under this Section 9
shall take place on the first business day falling at least 30 days after the
expiration of the 30-day period above, at the offices of the Company. At such
closing, the Major Investors shall acquire from the Company, and the Company
shall issue to the Major Investors, the number or amount of Offered Securities
being purchased by each Major Investor pursuant to the terms and conditions
hereof (including the terms and conditions specified in the Offer). The purchase
by the Major Investors of any Offered Securities is subject in all cases to the
preparation, execution and delivery by the Company and the Major Investors of a
purchase agreement relating to such Offered Securities reasonably satisfactory
in form and substance to the Major Investors and the Company.

                                       11

<PAGE>

     (d) Any Offered Securities not acquired by the Major Investors or other
persons in accordance with Section 9 above may not be issued, sold or exchanged
until they are again offered to the Major Investors under the procedures
specified in this Agreement.

     (e) The rights of the Major Investors under this Section 9 shall not apply
to:

          (i) Common Stock issued as a stock dividend to holders of Common Stock
     or upon any subdivision or combination of shares of Common Stock, or upon
     conversion of Preferred Stock;

          (ii) the issuance of any shares of Common Stock upon conversion of
     options, warrants, rights, and convertible and exchangeable securities (as
     long as the applicable options, warrants, rights, or convertible or
     exchangeable securities were outstanding on the date of this Agreement or
     were issued thereafter in compliance with this Agreement);

          (iii) the issuance of shares of Common Stock, or options exercisable
     therefor, including options outstanding on the date of this Agreement
     issued or issuable to officers, directors, consultants and employees of the
     Company or any Subsidiary, as approved by the Board of Directors or any
     duly authorized committee of the Board of Directors pursuant to any plan,
     agreement or arrangement approved by a majority of the members of the Board
     of Directors of the Company;

          (iv) the issuance of securities in consideration for the acquisition
     (whether by merger, share exchange or otherwise) by the Company or any of
     its Subsidiaries of the stock or assets of any other entity;

          (v) the issuance of shares of Common Stock by the Company in an
     underwritten public offering pursuant to an effective registration
     statement;

          (vi) the issuance of shares of Common Stock by the Company in
     connection with corporate partnering transactions, lease lines, equipment
     financings, bank financings or acquisitions of business or intellectual
     property rights, provided, that in each such case such transaction and
     issuance has been approved by the Board of Directors of the Company;

          (vii) securities as to which the Company has obtained a prior express
     written waiver of application of this Section 9 from the holders of at
     least a majority of the Series A Preferred Stock then outstanding; or

          (viii) the sale and issuance of any shares of Series A Preferred Stock
     pursuant to the terms of the Purchase Agreement.

     10. Drag-Along Right.

     (a) For purposes of this Section 10, a "Change of Control Transaction"
shall mean (x) any consolidation or merger of the Company with or into any other
corporation or other entity, or any other corporate reorganization, in which the
shareholders of the Company immediately prior to such consolidation, merger or
reorganization, own less than 50% of the Company's voting

                                       12

<PAGE>

power immediately after such consolidation, merger or reorganization; (y) any
transaction or series of related transactions (whether or not the Company is a
party) in which in excess of fifty percent (50%) of the Company's voting power
is transferred to a party or parties who were not shareholders or affiliates of
shareholders prior to such transfer (other than an equity financing exclusively
for capital raising purposes in which the Company is the surviving corporation,
including a transaction in which holders prior to such transaction own less than
50% of the total voting power of the Company immediately after the closing of
such financing); or (z) a sale, lease, transfer or other disposition (including,
without limitation, by an exclusive license of all or substantially all of its
rights in the material intellectual property of the Company for a term of at
least all or substantially all of the effective period of the material patents
included therein) of all or substantially all of the assets of the Company.

     (b) If at any time after May 1, 2009 one or more of the Investors
representing at least sixty-seven percent (67%) of the then issued and
outstanding Series A Preferred Stock (the "Approving Seller(s)") shall propose
to undertake a bona fide arm's length Change of Control Transaction with a third
party not affiliated with any of the Approving Sellers, then subject to the
provisions hereof, each Investor and Founder shall, if requested by such
Approving Seller(s) upon written notice at least twenty (20) days prior to the
date on which such transaction shall be consummated: (i) vote for, consent to
and/or not raise objections against (or seek dissenters, appraisal or similar
rights with respect to) such Change of Control Transaction, (ii) take all
necessary and desirable actions in connection with the consummation of the
Change of Control Transaction as reasonably requested by the Company or the
Approving Seller(s), including, without limitation, exercising any conversion
privileges (provided, however, that for purposes of determining the form and
amount of consideration payable for each share of Series A Preferred, each
holder thereof may elect to be treated as though it had not converted such
shares of Series A Preferred into shares of Common Stock), and (iii) if
applicable, deliver its share certificate(s) (accompanied by duly executed stock
powers or other instrument of transfer duly endorsed in blank) representing the
shares to the Company or to an agent designated by the Company, for the purpose
of effectuating the transfer of the shares to the purchaser and the disbursement
of the proceeds of such transactions to the Investors and Founders. The Company
may, at its option, deposit the consideration payable for the shares with a
depository designated by it and thereafter each share certificate shall
represent only the right to receive the consideration payable in the
transaction.

     (c) The obligations of the Investors and Founders pursuant to this Section
10 are subject to the satisfaction to the following conditions: (i) each
Investor and Founder shall receive in respect of their equity securities in the
Company, the same form of consideration in an amount per share of Series A
Preferred or Common Stock, respectively, as determined for each such class or
series in accordance with the liquidation preferences set forth in the Articles
of Incorporation of the Company, as amended; (ii) if any Investor or Founder is
given an option as to the form of consideration to be received, each Investor or
Founder holding the same class and series of capital stock shall be given the
same option; (iii) no Investor or Founder who holds any debt or other securities
issued by the Company (i.e., securities other than Series A Preferred or Common
Stock) shall, pursuant to the Change of Control Transaction, receive, in
consideration of such debt or other securities, an amount greater than the
amount provided pursuant to the terms of agreements evidencing such debt or
securities; (iv) no Investor or Founder shall be required to agree to any
covenant not to compete or covenant not to solicit customers, employees

                                       13

<PAGE>

or suppliers of any party to the Change of Control Transaction; (v) no Investor
or Founder shall be required to amend, extend or terminate any agreement with
the Company, the acquiring party or their respective affiliates (other than this
Agreement or the Ancillary Agreements (as defined in the Purchase Agreement));
(vi) no Investor or Founder shall be obligated by the acquisition documents to
make (without their consent) any out-of-pocket expenditure prior to the
consummation of the Change of Control Transaction and no Investor or Founder
shall be obliged to pay more than such Investor's or Founder's pro rata share
(based upon the amount of consideration received) of reasonable expenses
incurred in connection with a consummated Change of Control Transaction to the
extent such costs are incurred for the benefit of all shareholders of the
Company and are not otherwise paid by the Company or the acquiring party (for
purposes of clarification, costs incurred by or on behalf of an Investor or
Founder for such Investor's or Founder's sole benefit will not be considered
costs of the transaction hereunder); (vii) prior notice of a Change of Control
Transaction shall be provided to the Investors and the Founders at least 20 days
prior to the closing of such transaction, which notice shall provide the
identity of the acquiring entity involved in such Change of Control Transaction
and the material terms thereof; and (viii) except as otherwise specified in this
paragraph each Investor and Founder shall be treated similarly with respect to
their rights and obligations under the Change of Control Transaction agreements
as shareholders of the Company, taking into account the type of shares owned by
each and the consideration to be received by each in accordance with clause (i)
of this paragraph (including without limitation with respect to any escrow
provisions, earn-out or other contingent payment provisions, or indemnification
obligations).

     (d) Each Investor and Founder agrees that, except for encumbrances that are
created as a result of this Agreement, it will not permit any liens or other
encumbrances against the shares of the Company owned by it that would prohibit
the enforcement of the Investor's or Founder's obligations of this Section 10.

     (e) No Investor or Founder shall be required in connection with any Change
of Control Transaction to make any representations and warranties in connection
with such transaction except as to good title and the absence of liens with
respect to the shares to be sold by it, the corporate or other existence of the
holder and the authority, form, validity and binding effect of, and the absence
of any conflicts under the Investor's or Founder's articles and other formative
and governing documents of such Investor or Founders. No such Investor or
Founders shall be required to provide any personal indemnity in connection with
such Change of Control Transaction except for indemnities for damages resulting
from a breach of the above-stated representations and warranties and provided
that no such indemnity shall exceed the value of the consideration received by
such Investor or Founder pursuant to such Change of Control Transaction. For
purposes of explanation, the parties acknowledge that the Company may be
required to make other representations, warranties and indemnification in
connection with a Change of Control Transaction, and that the proceeds to be
received by the Investors and Founders in connection therewith may be subject to
escrow or other offset rights indirectly in connection with such
representations, warranties and indemnification.

     11. Assignments and Transfers; No Third Party Beneficiaries. This Agreement
and the rights and obligations of the parties hereunder shall inure to the
benefit of, and be binding upon, their respective successors, assigns and legal
representatives, but shall not otherwise be for the benefit of any third party.
The rights of the Investors hereunder are only assignable (a) by

                                       14

<PAGE>

each of such Investors to any other Investor, (b) to a current or former
partner, member or affiliate of such Investor or (c) to an assignee or
transferee who acquires shares of Common Stock (including shares of Common Stock
issuable upon conversion of Series A Preferred Stock) from the Investor, and in
each case such assignee shall then become a party to this Agreement as an
"Investor". As used herein, the term "affiliate" means, as to the entity in
question, any person or entity that directly or indirectly controls, is
controlled by or is under common control with the entity in question, and the
term "control" means possession, directly or indirectly, of the power to direct
or cause the direction of the management and policies of an entity whether
through ownership of voting securities, by contract, or otherwise. The
obligations of the Company, the Founders and the LSC Holders hereunder may not
be assigned without the consent of a majority in interest of the Investors.

     12. Legend. Each existing or replacement certificate for shares now owned
or hereafter acquired by the Founder or a LSC Holder shall bear the following
legend upon its face:

     "THE SALE, PLEDGE, HYPOTHECATION, ASSIGNMENT OR TRANSFER OF THE SECURITIES
     REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A
     CERTAIN RIGHT OF FIRST REFUSAL AND CO SALE AGREEMENT BY AND AMONG THE
     SHAREHOLDER, THE CORPORATION AND CERTAIN HOLDERS OF STOCK OF THE
     CORPORATION. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST
     TO THE SECRETARY OF THE CORPORATION."

     13. Effect of Change in Company's and LSC's Capital Structure. Appropriate
adjustments shall be made in the number and class of shares in the event of a
stock dividend, stock split, reverse stock split, combination, reclassification
or like change in the capital structure of the Company or LSC, respectively.

     14. Notices. All notices, requests, consents, and other communications
under this Agreement shall be in writing and shall be deemed delivered (a) three
business days after being sent by registered or certified mail, return receipt
requested, postage prepaid, (b) one business day after being sent via a
reputable nationwide overnight courier service guaranteeing next business day
delivery or (c) upon delivery when sent by facsimile (with confirmation of
receipt), in each case to the intended recipient at the address indicated for
such party on the signature page or Schedules hereto, as applicable, or at such
other address as such party may designate by ten (10) days' advance written
notice to the other parties.

     15. Term. This Agreement shall terminate upon the earlier of (a) the
consummation of a Qualified IPO (as defined in the Rights Agreement), (b) the
closing of a Change of Control (as defined in the Rights Agreement), (c) the
written agreement of the Company, the persons holding at least a majority in
interest of the Series A Preferred Stock then held by the Investors and their
assignees (pursuant to Section 11 hereof), the persons holding at least a
majority in interest of the Stock held by all of the Founders, and the persons
holding at least a majority in interest of the LSC Stock held by all of the LSC
Holders, or (d) the closing of a Change of Control Transaction effected pursuant
to Section 10.

                                       15

<PAGE>

     16. Entire Agreement. This Agreement contains the entire understanding of
the parties hereto with respect to the subject matter hereof, supersedes all
other agreements between or among any of the parties with respect to the subject
matter hereof and cannot be altered or otherwise amended except pursuant to an
instrument in writing signed by each of the parties to this Agreement.

     17. Amendments and Waivers. Any term of this Agreement may be amended and
the observance of any term of this Agreement may be waived (either generally or
in a particular instance and either retroactively or prospectively), only with
the written consent of (a) as to the Company, by the Company, (b) as to the
Investors, by persons holding at least a majority in interest of the Series A
Preferred Stock held by the Investors and their assignees, pursuant to Section
11 hereof, (c) as to each Founder, such Founder and (d) as to each LSC Holder,
such LSC Holder; provided that any Investor may waive any of his rights
hereunder without obtaining the consent of any other Investor. Notwithstanding
the foregoing, any amendment (i) to Section 10 that would materially change the
representations, covenants or indemnification that a Founder or Investor would
be required to provide in a Change of Control Transaction shall also require the
written consent of such Founder or Investor, and (ii) to Section 11 that would
remove an Investor's right to assign to its affiliates (or that would change the
definition of "affiliate" or "control" set forth therein) shall also require the
written consent of such Investor. Any amendment or waiver effected in accordance
with this Section 17 shall be binding upon each Investor, its successors and
assigns, the Company and the Founder in question.

     18. Separability. In case any provision of the Agreement shall be held to
be invalid, illegal or unenforceable, the validity, legality and/or
enforceability of the remaining provisions shall not in any way be affected or
impaired thereby.

     19. Attorney's Fees. In the event that any dispute among the parties to
this Agreement should result in litigation, the prevailing party in such dispute
shall be entitled to recover from the losing party all fees, costs and expenses
of enforcing any right of such prevailing party under or with respect to this
Agreement, including without limitation, such reasonable fees and expenses of
attorneys and accountants, which shall include, without limitation, all fees,
costs and expenses of appeals.

     20. Counterparts. This Agreement may be executed in any number of
counterparts, including by facsimile copy, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument.

     21. Further Instruments and Actions. The parties agree to execute such
further instruments and to take such further action as may reasonably be
necessary to carry out the intent of this Agreement. Each party agrees to
cooperate affirmatively with the Company, LSC, the Purchasers, the LSC Holders
and the Investors, to the extent reasonably requested by the Company, LSC, the
Purchasers, the LSC Holder or the Investors, to enforce rights and obligations
pursuant thereto.

     22. Equitable Remedies. The Company, LSC, the Founders, the LSC Holders and
the Investors each acknowledge and agree that the legal remedies available to
each party in the event a party violates any covenant in this Agreement would be
inadequate and that the non-parties

                                       16

<PAGE>

shall be entitled, without posting any bond or other security, to temporary,
preliminary and permanent injunctive relief, specific performance and other
equitable remedies in the event of such a violation, in addition to any other
remedies which such party may have at law or in equity.

     23. Governing Law; Jurisdiction; Venue; No Jury Trial. This Agreement shall
be governed by and construed in accordance with the laws of the State of
Washington and the laws of the United States applicable therein (in each case
without giving effect to any choice or conflict of laws provision or rule that
would cause the application of the laws of any other jurisdiction) and shall be
treated in all respects as a Washington contract. Any action, suit or proceeding
arising out of or relating to this Agreement shall be brought in the state
courts of the State of Washington located in King County, or, if it has or can
acquire jurisdiction, any Federal court located in such State and County, and
EACH OF THE PARTIES HERETO, AFTER CONSULTING WITH OR HAVING HAD THE OPPORTUNITY
TO CONSULT WITH COUNSEL, HEREBY KNOWINGLY, VOLUNTARILY, INTENTIONALLY AND
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS AND WAIVES
TRIAL BY JURY, IN EACH CASE IN CONNECTION WITH ANY ACTION, SUIT OR PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT. Each of the parties hereto hereby
irrevocably and unconditionally waives any objection to the laying of venue of
any action, suit or proceeding arising out of or relating to this Agreement or
the transactions contemplated hereby in the courts of the State of Washington or
the United States of America, in each case located in King County, and hereby
further irrevocably and unconditionally waives and agrees not to plead or claim
in any such court that any such matter brought in any such court has been
brought in an inconvenient forum

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

                                       17

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Right of First
Refusal and Co-Sale Agreement as of the date first written above.

THE COMPANY:                            LIGHT SCIENCES ONCOLOGY, INC.

                                        By: /s/ Llew Keltner
                                            ------------------------------------
                                        Its: Chief Executive Officer
                                        Address:                               .
                                                 ------------------------------
                                        Fax No:
                                                --------------------------------

FOUNDERS:

                                        LIGHT SCIENCES CORPORATION

                                        By: /s/ Albert Luderer
                                            ------------------------------------
                                        Its: Chief Executive Officer

INVESTORS:

                                        ESSEX WOODLANDS HEALTH
                                        VENTURES FUND VI, L.P.

                                        By: Essex Woodlands Health Ventures VI,
                                            L.P.
                                        Its: General Partner

                                        By: Essex Woodlands Health Ventures VI,
                                            L.L.C.
                                        Its: General Partner

                                        By: /s/ Jeff Himawan
                                            ------------------------------------
                                            Dr. Jeff Himawan, Managing Director

<PAGE>

                                   SCHEDULE I

                                    FOUNDERS

<TABLE>
<CAPTION>
Founder Name and Address     Shares of Common Stock Held
------------------------     ---------------------------
<S>                          <C>
Light Sciences Corporation            7,743,040

TOTAL                                 7,743,040
</TABLE>

<PAGE>

                                   SCHEDULE II

                                    INVESTORS

<TABLE>
<CAPTION>
Investor Name and Address                      Series A Shares Held
-------------------------                      --------------------
<S>                                            <C>
ESSEX WOODLANDS HEALTH VENTURE FUND VI, L.P.         3,200,000

CRAIG WATJEN                                         1,424,989

ADAMS STREET V, L.P.                                 1,000,000

CHINA DEVELOPMENT INDUSTRIAL BANK, INC.                400,000

EDWARD AVEDISIAN                                       200,000

HSIU-CHUAN LEE                                          20,000

JOHNSON & JOHNSON DEVELOPMENT CORPORATION              800,000

TOTAL                                                7,044,989
</TABLE>
<PAGE>

                                  SCHEDULE III

                               LSC COMMON HOLDERS

Craig Watjen
14571 Southeast 51st St.
Bellevue, Wa. 98006
Fax: (425) 649-9898

James Chen
c/o Light Sciences Corporation
34931 SE Douglas Street
Suite 200
Snoqualmie, WA 98065

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]